Nanotools for megaproblems: Probing protein misfolding diseases using nanomedicine modus operandi

Journal of Proteome Research

Volumn 5, Issue 10, 2006, Pages 2505-2522

  Uversky, Vladimir N ^a,b,c   Kabanov, Alexander V ^d   Lyubchenko, Yuri L ^d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE FOR BIOLOGICAL INSTRUMENTATION   (Russian Federation)

^c Molecular Kinetics Inc   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Conformational disease; Misfolding; Nanomedicine; Partially folded intermediate; Protein aggregation

Indexed keywords

AMYLOID PROTEIN;

AMYLOIDOSIS; ATOMIC FORCE MICROSCOPY; CONFORMATIONAL TRANSITION; DEGENERATIVE DISEASE; FLUORESCENCE MICROSCOPY; NANOTECHNOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN MISFOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

AMYLOIDOSIS; HUMANS; NANOMEDICINE; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES; PROTEIN FOLDING;

EID: 33750127122     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr0603349     Document Type: Review

References (220)

1. Cohen, A. S. General introduction and a brief history of the amyloid fibril. In Amyloidosis; Marrink, J., Van Rijswijk, M. H., Eds.; Martinus Nijhoff: Dordrecht, The Netherlands, 1986; pp 3-19.
2. Virchow, R. Cellulose-Frage. Virchows Arch. Pathol. Anat. 1854, 6, 416-426.
3. Friedreich, N. K., A. Zur Amyloidfrage. Virchows Arch. Pathol. Anat. 1859, 15, 50-65.
4. Hanssen, O. Ein Beitrag zur Chemie der amyloiden Entartung. Biochem. Z. 1908, 13, 185-198.
5. Alzheimer, A. Über eine eigenartige Eskrankung der Nirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. 1907, 64, 146-148.
6. Forman, M. S.; Trojanowski, J. Q.; Lee, V. M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 2004, 10, 1055-1063.
7. Lewy, F. Paralysis agitans. In Pathologische Anatomie. Handbuch der Neurologie; Lewandowski, M., Abelsdorff, G., Eds.; Springer Vertag: Berlin, Germany, 1912; pp 920-933.
8. Westermark, P. Amyloidosis and amyloid proteins: brief history and definitions. In Amyloid Proteins. The Beta Sheet Conformation and Disease; Sipe, J. D., Ed.; Wiley-VCH Verlag GmbH & Co. KGaA; Weinheim, Germany, 2005; pp 3-28.
9. Kelly, J. W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 1998, 8, 101-106.
10. Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 1999, 24, 329-332.
11. Dobson, C. M. Principles of protein folding, misfolding and aggregation. Semin. Cell Dev. Biol. 2004, 15, 3-16.
12. Bellotti, V.; Mangione, P.; Stoppini, M. Biological activity and pathological implications of misfolded proteins. Cell. Mol. Life Sci. 1999, 55, 977-991.
13. Rochet, J. C.; Lansbury, P. T., Jr. Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 2000, 10, 60-68.
14. Uversky, V. N.; Fink, A. L. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim. Biophys. Acta 2004, 1698, 131-153.
15. Sunde, M.; Blake, C. C. From the globular to the fibrous state: protein structure and structural conversion in amyloid formation. Q. Rev. Biophys. 1998, 31, 1-39.
16. Uversky, V. N.; Talapatra, A.; Gillespie, J. R.; Fink, A. L. Protein deposits as the molecular basis of amyloidosis: I. Systemic Amyloidoses. Med. Sci. Monit. 1999, 5, 1001-1012.
17. Uversky, V. N.; Talapatra, A.; Gillespie, J. R.; Fink, A. L. Protein deposits as the molecular basis of amyloidosis: II. Localized amyloidosis and neurodegenerative disordres. Med. Sci. Monit. 1999, 5, 1238-1254.
18. Uversky, V. N.; Li, J.; Fink, A. L. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J. Biol. Chem. 2001, 276, 10737-10744.
19. Uversky, V. N.; Li, J.; Souillac, P.; Millett, I. S.; Doniach, S.; Jakes, R.; Goedert, M.; Fink, A. L. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J. Biol. Chem. 2002, 277, 11970-11978.
20. Glenner, G. G.; Ein, D.; Eanes, E. D.; Bladen, H. A.; Terry, W.; Page, D. L. Creation of "amyloid" fibrils from Bence Jones proteins in vitro. Science 1971, 174, 712-714.
21. Glenner, G. G.; Eanes, E. D.; Bladen, H. A.; Linke, R. P.; Termine, J. D. Beta-pleated sheet fibrils. A comparison of native amyloid with synthetic protein fibrils. J. Histochem. Cytochem. 1974, 22, 1141-1158.
22. Perutz, M. F. Amyloid fibrils. Mutations make enzyme polymerize. Nature 1997, 385, 773, 775.
23. Jahn, T. R.; Radford, S. E. The Yin and Yang of protein folding. FEBS J. 2005, 272, 5962-5970.
24. Chiti, F.; Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Biochem. 2006, 75, 333-366.
25. Smith, D. P.; Jones, S.; Serpell, L. C.; Sunde, M.; Radford, S. E. A systematic investigation into the effect of protein destabilisation on beta 2-microglobulin amyloid formation. J. Mol. Biol. 2003, 330, 943-954.
26. Selkoe, D. J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997, 275, 630-631.
27. Urbanc, B.; Cruz, L.; Le, R.; Sanders, J.; Ashe, K. H.; Duff, K.; Stanley, H. E.; Irizarry, M. C.; Hyman, B. T. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13990-13995.
28. Mucke, L.; Masliah, E.; Yu, G. Q.; Mallory, M.; Rockenstein, E. M.; Tatsuno, G.; Hu, K.; Kholodenko, D.; Johnson-Wood, K.; McConlogue, L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 2000, 20, 4050-4058.
29. Lashuel, H. A.; Hartley, D.; Petre, B. M.; Walz, T.; Lansbury, P. T., Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature 2002, 418, 291.
30. Lashuel, H. A.; Petre, B. M.; Wall, J.; Simon, M.; Nowak, R. J.; Walz, T.; Lansbury, P. T., Jr. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 2002, 322, 1089-1102.
31. Uversky, V. N. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn. 2003, 21, 211-234.
32. Stefani, M. Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim. Biophys. Acta 2004, 1739, 5-25.
33. Gregersen, N.; Bross, P.; Vang, S.; Christensen, J. H. Protein misfolding and human disease. Annu. Rev. Genomics Hum. Genet. 2006, in press.
34. Ikeda, S. Cardiac amyloidosis: heterogenous pathogenic backgrounds. Intern. Med. (Tokyo) 2004, 43, 1107-1114.
35. Munar-Ques, M.; Saraiva, M. J.; Viader-Farre, C.; Zabay-Becerril, J. M.; Mulet-Ferrer, J. Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain). Amyloid 2005, 12, 54-61.
36. van der Hilst, J. C.; Simon, A.; Drenth, J. P. Hereditary periodic fever and reactive amyloidosis. Clin. Exp. Med. 2005, 5, 87-98.
37. Pepys, M. B.; Hawkins, P. N.; Booth, D. R.; Vigushin, D. M.; Tennent, G. A.; Soutar, A. K.; Totty, N.; Nguyen, O.; Blake, C. C.; Terry, C. J.; et al. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 1993, 362, 553-557.
38. Gambetti, P.; Parchi, P.; Chen, S. G. Hereditary Creutzfeldt-Jakob disease and fatal familial insomnia. Clin. Lab. Med. 2003, 23, 43-64.
39. Nussbaum, R. L.; Polymeropoulos, M. H. Genetics of Parkinson's disease. Hum. Mol. Genet. 1997, 6, 1687-1691.
40. Kruger, R. Genes in familial parkinsonism and their role in sporadic Parkinson's disease. J. Neurol. 2004, 251 (Suppl. 6), VI/2-6.
41. Imbimbo, B. P.; Lombard, J.; Pomara, N. Pathophysiology of Alzheimer's disease. Neuroimaging Clin. N. Am. 2005, 15, 727-753.
42. Ratnaswamy, G.; Koepf, E.; Bekele, H.; Yin, H.; Kelly, J. W. The amyloidogenicity of gelsolin is controlled by proteolysis and pH. Chem. Biol. 1999, 6, 293-304.
43. Bellotti, V.; Gallieni, M.; Giorgetti, S.; Brancaccio, D. Dynamic of beta(2)-microglobulin fibril formation and reabsorption: the role of proteolysis. Semin. Dial. 2001, 14, 117-122.
44. Goldberg, A. L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426, 895-899.
45. de Laureto, P. P.; Frare, E.; Battaglia, F.; Mossuto, M. F.; Uversky, V. N.; Fontana, A. Protein dissection enhances the amyloidogenic properties of alpha-lactalbumin. FEBS J. 2005, 272, 2176-2188.
46. Uversky, V. N. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 2004, 318, 225-241.
47. Betarbet, R.; Canet-Aviles, R. M.; Sherer, T. B.; Mastroberardino, P. G.; McLendon, C.; Kim, J. H.; Lund, S.; Na, H. M.; Taylor, G.; Bence, N. F.; Kopito, R.; Seo, B. B.; Yagi, T.; Yagi, A.; Klinefelter, G.; Cookson, M. R.; Greenamyre, J. T. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol. Dis. 2006, 22, 404-420.
48. Liu, J.; Chen, Q.; Huang, W.; Horak, K. M.; Zheng, H.; Mestril, R.; Wang, X. Impairment of the ubiquitin-proteasome system in desminopathy mouse hearts. FASEB J. 2006, 20, 362-364.
49. Lyubchenko, Y. L.; Sherman, S.; Shlyakhtenko, L. S.; Uversky, V. N. Nanoimaging for protein misfolding and related diseases. J. Cell. Biochem. 2006, in press.
50. Sipe, J. D.; Cohen, A. S. Review: history of the amyloid fibril. J. Struct. Biol. 2000, 130, 88-98.
51. Divry, P.; Florkin, M. Sur les proprietes optiques de l'amyloide. C. R. Soc. Biol. 1927, 97, 1808-1810.
52. Cohen, A. S.; Calkins, E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 1959, 183, 1202-1203.
53. Shirahama, T.; Cohen, A. S. High-resolution electron microscopic analysis of the amyloid fibril. J. Cell Biol. 1967, 33, 679-708.
54. Shirahama, T.; Cohen, A. S. Reconstitution of amyloid fibrils from alkaline extracts. J. Cell Biol. 1967, 35, 459-464.
55. Shirahama, T.; Cohen, A. S. A brief review of the ultrastructure of amyloid. In Amyloidosis; Marrink, J., Van Rijswijk, M. H., Eds.; Martinus Nijhoff: Dordrecht, The Netherlands, 1986; pp 51-57.
56. DeRosier, D. J.; Klug, A. Reconstruction of three-dimensional structures from electron micrographs. Nature 1968, 217, 130-134.
57. Stewart, M. Computer image processing of electron micrographs of biological structures with helical symmetry. J. Electron Microsc. Tech. 1988, 9, 325-358.
58. Saibil, H. R. Macromolecular structure determination by cryoelectron microscopy. Acta Crystallogr., D: Biol. Crystallogr. 2000, 56, 1215-1222.
59. Serpell, L. C.; Sunde, M.; Benson, M. D.; Tennent, G. A.; Pepys, M. B.; Fraser, P. E. The protofilament substructure of amyloid fibrils. J. Mol. Biol. 2000, 300, 1033-1039.
60. Jimenez, J. L.; Guijarro, J. I.; Orlova, E.; Zurdo, J.; Dobson, C. M.; Sunde, M.; Saibil, H. R. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 1999, 18, 815-821.
61. Khurana, R.; Ionescu-Zanetti, C.; Pope, M.; Li, J.; Nielson, L.; Ramirez-Alvarado, M.; Regan, L.; Fink, A. L.; Carter, S. A. A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy. Biophys. J. 2003, 85, 1135-1144.
62. Bonar, L.; Cohen, A. S.; Skinner, M. M. Characterization of the amyloid fibril as a cross-beta protein. Proc. Soc. Exp. Biol. Med. 1969, 131, 1373-1375.
63. Perutz, M. F.; Finch, J. T.; Berriman, J.; Lesk, A. Amyloid fibers are water-filled nanotubes. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 5591-5595.
64. Petkova, A. T.; Buntkowsky, G.; Dyda, F.; Leapman, R. D.; Yau, W. M.; Tycko, R. Solid-state NMR reveals a pH-dependent antiparallel beta-sheet registry in fibrils formed by a beta-amyloid peptide. J. Mol. Biol. 2004, 335, 247-260.
65. Petkova, A. T.; Ishii, Y.; Balbach, J. J.; Antzutkin, O. N.; Leapman, R. D.; Delaglio, F.; Tycko, R. A structural model for Alzheimer's beta-amyloid fibrils based on experimental constraints from solid-state NMR. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 16742-16747.
66. Balbach, J. J.; Ishii, Y.; Antzutkin, O. N.; Leapman, R. D.; Rizzo, N. W.; Dyda, F.; Reed, J.; Tycko, R. Amyloid fibril formation by A beta 16-22, a seven-residue fragment of the Alzheimer's beta-amyloid peptide, and structural characterization by solid-state NMR. Biochemistry 2000, 39, 13748-13759.
67. Chan, J. C.; Oyler, N. A.; Yau, W. M.; Tycko, R. Parallel beta-sheets and polar zippers in amyloid fibrils formed by residues 10-39 of the yeast prion protein Ure2p. Biochemistry 2005, 44, 10669-10680.
68. Nelson, R.; Eisenberg, D. Recent atomic models of amyloid fibril structure. Curr. Opin. Struct. Biol. 2006, 16, 260-265.
69. Makin, O. S.; Serpell, L C. Examining the structure of the mature amyloid fibril. Biochem. Soc. Trans. 2002, 30, 521-525.
70. Makin, O. S.; Serpell, L. C. Structures for amyloid fibrils. FEBS J. 2005, 272, 5950-5961.
71. Makin, O. S.; Serpell, L. C. X-ray diffraction studies of amyloid structure. Methods Mol. Biol. 2005, 299, 67-80.
72. Makin, O. S.; Atkins, E.; Sikorski, P.; Johansson, J.; Serpell, L. C. Molecular basis for amyloid fibril formation and stability. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 315-320.
73. Dobson, C. M. Experimental investigation of protein folding and misfolding. Methods 2004, 34, 4-14.
74. Dobson, C. M. Structural biology: prying into prions. Nature 2005, 435, 747-749.
75. Ha, T.; Enderle, T.; Ogletree, D. F.; Chemla, D. S.; Selvin, P. R.; Weiss, S. Probing the interaction between two single molecules: fluorescence resonance energy transfer between a single donor and a single acceptor. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6264-6268.
76. Weiss, S. Fluorescence spectroscopy of single biomolecules. Science 1999, 283, 1676-1683.
77. Weiss, S. Measuring conformational dynamics of biomolecules by single molecule fluorescence spectroscopy. Nat. Struct. Biol. 2000, 7, 724-729.
78. Deniz, A. A.; Dahan, M.; Grunwell, J. R.; Ha, T.; Faulhaber, A. E.; Chemla, D. S.; Weiss, S.; Schultz, P. G. Single-pair fluorescence resonance energy transfer on freely diffusing molecules: observation of Forster distance dependence and subpopulations. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 3670-3675.
79. Deniz, A. A.; Laurence, T. A.; Beligere, G. S.; Dahan, M.; Martin, A. B.; Chemla, D. S.; Dawson, P. E.; Schultz, P. G.; Weiss, S. Single-molecule protein folding: diffusion fluorescence resonance energy transfer studies of the denaturation of chymotrypsin inhibitor 2. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 5179-5184.
80. Ha, T.; Ting, A. Y.; Liang, J.; Caldwell, W. B.; Deniz, A. A.; Chemla, D. S.; Schultz, P. G.; Weiss, S. Single-molecule fluorescence spectroscopy of enzyme conformational dynamics and cleavage mechanism. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 893-898.
81. Tokunaga, M.; Kitamura, K.; Saito, K.; Iwane, A. H.; Yanagida, T. Single molecule imaging of fluorophores and enzymatic reactions achieved by objective-type total internal reflection fluorescence microscopy. Biochem. Biophys. Res. Commun. 1997, 235, 47-53.
82. Smith, D. E.; Babcock, H. P.; Chu, S. Single-polymer dynamics in steady shear flow. Science 1999, 283, 1724-1727.
83. Zhuang, X.; Bartley, L. E.; Babcock, H. P.; Russell, R.; Ha, T.; Herschlag, D.; Chu, S. A single-molecule study of RNA catalysis and folding. Science 2000, 288, 2048-2051.
84. Rhoades, E.; Cohen, M.; Schuler, B.; Haran, G. Two-state folding observed in individual protein molecules. J. Am. Chem. Soc. 2004, 126, 14686-14687.
85. Tcherkasskaya, O.; Ptitsyn, O. B. Direct energy transfer to study the 3D structure of non-native proteins: AGH complex in molten globule state of apomyoglobin. Protein Eng. 1999, 12, 485-490.
86. Lakowicz, J. R. Principles of Fluorescence Spectroscopy; Plenum Press: New York, 1983.
87. Cheung, H. C. Resonance energy transfer. In Topics in Fluorescence Spectroscopy, Lakowicz, J. R., Ed.; Plenum Press: New York, 1991; pp 127-176.
88. Lundblad, R. L. Chemical Reagents for Protein Modification; CRC Press: Boca Raton, Florida, 1991.
89. Borkman, R. F.; Phillips, S. R. Tyrosine-to-tryptophan energy transfer and the structure of calf gamma-II Crystallin. Exp. Eye Res. 1985, 40, 819-826.
90. Wu, P.; Brand, L. Resonance energy transfer: methods and applications. Anal. Biochem 1994, 218, 1-13.
91. Rischel, C.; Thyberg, P.; Rigler, F.; Poulsen, F. M. Time-resolved fluorescence studies of the molten globule state of apomyoglobin. J. Mol. Biol. 1996, 257, 877-885.
92. Uversky, V. N.; Fink, A. L. Do protein molecules have a native-like topology in the pre-molten globule state? Biochemistry (Moscow, Russ. Ed.) 1999, 64, 552-555.
93. Tcherkasskaya, O.; Uversky, V. N. Denatured collapsed states in protein folding: example of apomyoglobin. Proteins 2001, 44, 244-254.
94. Lee, J. C.; Langen, R.; Hummel, P. A.; Gray, H. B.; Winkler, J. R. Alpha-synuclein structures from fluorescence energy-transfer kinetics: implications for the role of the protein in Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 16466-16471.
95. Kaylor, J.; Bodner, N.; Edridge, S.; Yamin, G.; Hong, D. P.; Fink, A. L. Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W/Y133F/Y136F alpha-synuclein. J. Mol. Biol. 2005, 353, 357-372.
96. De Filippis, V.; Frasson, R.; Fontana, A. 3-Nitrotyrosine as a spectroscopic probe for investigating protein protein interactions. Protein Sci. 2008, 15, 976-986.
97. Berney, C.; Danuser, G. FRET or no FRET: a quantitative comparison. Biophys. J. 2003, 84, 3992-4010.
98. Xia, Z.; Liu, Y. Reliable and global measurement of fluorescence resonance energy transfer using fluorescence microscopes. Biophys. J. 2001, 81, 2395-2402.
99. Lantsman, K.; Tombes, R. M. CaMK-II oligomerization potential determined using CFP/YFP FRET. Biochim. Biophys. Acta 2005, 1746, 45-54.
100. Hudmon, A.; Schulman, H. Neuronal CA2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function. Annu. Rev. Biochem. 2002, 71, 473-510.
101. Tombes, R. M.; Faison, M. O.; Turbeville, J. M. Organization and evolution of multifunctional Ca(2+)/CaM-dependent protein kinase genes. Gene 2003, 322, 17-31.
102. Kanaseki, T.; Ikeuchi, Y.; Sugiura, H.; Yamauchi, T. Structural features of Ca2+/calmodulin-dependent protein kinase II revealed by electron microscopy. J. Cell Biol. 1991, 115, 1049-1060.
103. Kolodziej, S. J.; Hudmon, A.; Waxham, M. N.; Stoops, J. K. Three-dimensional reconstructions of calcium/calmodulin-dependent (CaM) kinase IIalpha and truncated CaM kinase IIalpha reveal a unique organization for its structural core and functional domains. J. Biol. Chem. 2000, 275, 14354-14359.
104. Hoelz, A.; Nairn, A. C.; Kuriyan, J. Crystal structure of a tetradecameric assembly of the association domain of Ca2+/calmodulin-dependent kinase II. Mol. Cell 2003, 11, 1241-1251.
105. Gaertner, T. R.; Kolodziej, S. J.; Wang, D.; Kobayashi, R.; Koomen, J. M.; Stoops, J. K.; Waxham, M. N. Comparative analyses of the three-dimensional structures and enzymatic properties of alpha, beta, gamma and delta isoforms of Ca2+-calmodulin-dependent protein kinase II. J. Biol. Chem. 2004, 279, 12484-12494.
106. Hohng, S.; Joo, C.; Ha, T. Single-molecule three-color FRET. Biophys. J. 2004, 87, 1328-1337.
107. Clamme, J. P.; Deniz, A. A. Three-color single-molecule fluorescence resonance energy transfer. ChemPhysChem 2005, 6, 74-77.
108. Brennan, J. D. Using intrinsic fluorescence to investigate proteins entrapped in sol-gel derived materials. Appl. Spectrosc. 1999, 53, 106A-121A.
109. Gill, I.; Ballesteros, A. Bioencapsulation within synthetic polymers (Part 1): sol-gel encapsulated biologicals. Trends Biotechnol. 2000, 18, 282-296.
110. Gill, I.; Ballesteros, A. Bioencapsulation within synthetic polymers (Part 2): non-sol-gel protein-polymer biocomposites. Trends Biotechnol. 2000, 18, 469-479.
111. Eggers, D. K.; Valentine, J. S. Crowding and hydration effects on protein conformation: a study with sol-gel encapsulated proteins. J. Mol. Biol. 2001, 314, 911-922.
112. Eggers, D. K.; Valentine, J. S. Molecular confinement influences protein structure and enhances thermal protein stability. Protein Sci. 2001, 10, 250-261.
113. Dave, B. C.; Dunn, B.; Valentine, J. S.; Zink, J. I. Sol-gel encapsulation methods for biosensors. Anal. Chem. 1994, 66, 1120A-1127A.
114. Shen, C.; Kostic, N. M. Kinetics of photoinduced electron-transfer reactions within sol-gel silica glass doped with zinc cytochrome c. Study of electrostatic effects in confined liquids. J. Am. Chem. Soc. 1997, 119, 9, 1304-1312.
115. Badjic, J.; Kostic, N. M. Effects of encapsulation in sol-gel silica glass on esterase activity, conformational stability, and unfolding of bovine carbonic anhydrase II. Chem. Mater. 1999, 11, 3671-3679.
116. Lan, E. H.; Dave, B. C.; Fukuto, J. M.; Dunn, B.; Zink, J. I.; Valentine, J. S. Synthesis of sol-gel encapsulated heme proteins with chemical sensing properties. J. Mater. Chem. 1999, 9, 45-53.
117. Rief, M.; Gautel, M.; Oesterhelt, F.; Fernandez, J. M.; Gaub, H. E. Reversible unfolding of individual titin immunoglobulin domains by AFM. Science 1997, 276, 1109-1112.
118. McAllister, C.; Karymov, M. A.; Kawano, Y.; Lushnikov, A. Y.; Mikheikin, A.; Uversky, V. N.; Lyubchenko, Y. L. Protein interactions and misfolding analyzed by AFM force spectroscopy. J. Mol. Biol. 2005, 354, 1028-1042.
119. Kransnoslobodtsev, A. V.; Shlyakhtenko, L. S.; Ukraintsev, E.; Zaikova, T. O.; Keana, J. F.; Lyubchenko, Y. L. Nanomedicine and protein misfolding diseases. Nanomedicine 2005, 1, 300-305.
120. Ban, T.; Hamada, D.; Hasegawa, K.; Naiki, H.; Goto, Y. Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence. J. Biol. Chem. 2003, 270, 16462-16465.
121. Ban, T.; Hoshino, M.; Takahashi, S.; Hamada, D.; Hasegawa, K.; Naiki, H.; Goto, Y. Direct observation of A beta amyloid fibril growth and inhibition. J. Mol. Biol. 2004, 344, 757-767.
122. Kowalewski, T.; Holtzman, D. M. In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet formation. Proc. Natl. Acad. Sci. U.S.A. 1989, 96, 3688-3693.
123. Hoyer, W.; Cherny, D.; Subramaniam, V.; Jovin, T. M. Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy. J. Mol. Biol. 2004, 340, 127-139.
124. Smith, L. J. Computational methods for generating models of denatured and partially folded proteins. Methods 2004, 34, 144-150.
125. Wickner, R. B. [URE3] as an altered URE2 protein: evidence for a prion analog in Saccharomyces cerevisiae. Science 1994, 264, 566-569.
126. Patino, M. M.; Liu, J. J.; Glover, J. R.; Lindquist, S. Support for the prion hypothesis for inheritance of a phenotypic trait in yeast. Science 1996, 273, 622-626.
127. Serio, T. R.; Cashikar, A. G.; Kowal, A. S.; Sawicki, G. J.; Moslehi, J. J.; Serpell, L.; Arnsdorf, M. F.; Lindquist, S. L. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 2000, 209, 1317-1321.
128. Serio, T. R.; Lindquist, S. L. Protein-only inheritance in yeast: something to get [PSI+]-ched about. Trends Cell Biol. 2000, 10, 98-105.
129. King, C. Y.; Diaz-Avalos, R. Protein-only transmission of three yeast prion strains. Nature 2004, 420, 319-323.
130. Nelson, R.; Sawaya, M. R.; Balbirnie, M.; Madsen, A. O.; Riekel, C.; Grothe, R.; Eisenberg, D. Structure of the cross-beta spine of amyloid-like fibrils. Nature 2005, 435, 773-778.
131. Liu, R.; McAllister, C.; Lyubchenko, Y.; Sierks, M. R. Residues 17-20 and 30-35 of beta-amyloid play critical roles in aggregation. J. Neurosci. Res. 2004, 75, 162-171.
132. Dawson, T. M.; Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302, 819-822.
133. Recchia, A.; Debetto, P.; Negro, A.; Guidolin, D.; Skaper, S. D.; Giusti, P. Alpha-synuclein and Parkinson's disease. FASEB J. 2004, 18, 617-626.
134. Muchowski, P. J.; Wacker, J. L. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 2005, 6, 11-22.
135. Zappacosta, F.; Pessi, A.; Bianchi, E.; Venturini, S.; Sollazzo, M.; Tramontano, A.; Marino, G.; Pucci, P. Probing the tertiary structure of proteins by limited proteolysis and mass spectrometry: the case of Minibody. Protein Sci. 1996, 5, 802-813.
136. Hubbard, S. J.; Eisenmenger, F.; Thornton, J. M. Modeling studies of the change in conformation required for cleavage of limited proteolytic sites. Protein Sci. 1994, 3, 757-768.
137. Hubbard, S. J.; Beynon, R. J.; Thornton, J. M. Assessment of conformational parameters as predictors of limited proteolytic sites in native protein structures. Protein Eng. 1998, 11, 349-359.
138. Laskowski, M., Jr.; Kato, I. Protein inhibitors of proteinases. Annu. Rev. Biochem. 1980, 49, 593-626.
139. Bode, W.; Huber, R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur. J. Biochem. 1992, 204, 433-451.
140. Hubbard, S. J.; Campbell, S. F.; Thornton, J. M. Molecular recognition. Conformational analysis of limited proteolytic sites and serine proteinase protein inhibitors. J. Mol. Biol. 1991, 220, 507-530.
141. Fontana, A.; Fassina, G.; Vita, C.; Dalzoppo, D.; Zamai, M.; Zambonin, M. Correlation between sites of limited proteolysis and segmental mobility in thermolysin. Biochemistry 1986, 25, 1847-1851.
142. Novotny, J.; Bruccoleri, R. E. Correlation among sites of limited proteolysis, enzyme accessibility and segmental mobility. FEBS Lett. 1987, 211, 185-189.
143. Fontana, A.; Zambonin, M.; Polverino de Laureto, P.; De Filippis, V.; Clementi, A.; Scaramella, E. Probing the conformational state of apomyoglobin by limited proteolysis. J. Mol. Biol. 1997, 266, 223-230.
144. Fontana, A.; Polverino de Laureto, P.; De Filippis, V.; Scaramella, E.; Zambonin, M. Probing the partly folded states of proteins by limited proteolysis. Folding Des. 1997, 2, R17-26.
145. Myers, S. L.; Thomson, N. H.; Radford, S. E.; Ashcroft, A. E. Investigating the structural properties of amyloid-like fibrils formed in vitro from beta2-microglobulin using limited proteolysis and electrospray ionisation mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20, 1628-1636.
146. Monti, M.; Amoresano, A.; Giorgetti, S.; Bellotti, V.; Pucci, P. Limited proteolysis in the investigation of beta2-microglobulin amyloidogenic and fibrillar states. Biochim. Biophys. Acta 2005, 1753, 44-50.
147. Polverino de Laureto, P.; Taddei, N.; Frare, E.; Capanni, C.; Costantini, S.; Zurdo, J.; Chiti, F.; Dobson, C. M.; Fontana, A. Protein aggregation and amyloid fibril formation by an SH3 domain probed by limited proteolysis. J. Mol. Biol. 2003, 334, 129-141.
148. Kheterpal, I.; Williams, A.; Murphy, C.; Bledsoe, B.; Wetzel, R. Structural features of the Abeta amyloid fibril elucidated by limited proteolysis. Biochemistry 2001, 40, 11757-11767.
149. Kheterpal, I.; Zhou, S.; Cook, K. D.; Wetzel, R. Abeta amyloid fibrils possess a core structure highly resistant to hydrogen exchange. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13597-13601.
150. Kheterpal, I.; Lashuel, H. A.; Hartley, D. M.; Walz, T.; Lansbury, P. T., Jr.; Wetzel, R. Abeta protofibrils possess a stable core structure resistant to hydrogen exchange. Biochemistry 2003, 42, 14092-14098.
151. Kheterpal, I.; Wetzel, R.; Cook, K. D. Enhanced correction methods for hydrogen exchange-mass spectrometric studies of amyloid fibrils. Protein Sci. 2003, 12, 635-643.
152. Williams, A. D.; Portelius, E.; Kheterpal, I.; Guo, J. T.; Cook, K. D.; Xu, Y.; Wetzel, R. Mapping abeta amyloid fibril secondary structure using scanning proline mutagenesis. J. Mol. Biol. 2004, 335, 833-842.
153. Kheterpal, I.; Chen, M.; Cook, K. D.; Wetzel, R. Structural differences in Abeta amyloid protofibrils and fibrils mapped by hydrogen exchange-mass spectrometry with on-line proteolytic fragmentation. J. Mol. Biol. 2006, 361, 785-795.
154. Ross, C. A.; Poirier, M. A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10 Suppl., S10-17.
155. O'Nuallain, B.; Wetzel, R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 1485-1490.
156. Glabe, C. G. Conformation-dependent antibodies target diseases of protein misfolding. Trends Biochem. Sci. 2004, 29, 542-547.
157. Emadi, S.; Liu, R.; Yuan, B.; Schulz, P.; McAllister, C.; Lyubchenko, Y.; Messer, A.; Sierks, M. R. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments. Biochemistry 2004, 43, 2871-2878.
158. Peretz, D.; Williamson, R. A.; Kaneko, K.; Vergara, J.; Leclerc, E.; Schmitt-Ulms, G.; Mehlhorn, I. R.; Legname, G.; Wormald, M. R.; Rudd, P. M.; Dwek, R. A.; Burton, D. R.; Prusiner, S. B. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001, 412, 739-743.
159. Dumoulin, M.; Last, A. M.; Desmyter, A.; Decanniere, K.; Canet, D.; Larsson, G.; Spencer, A.; Archer, D. B.; Sasse, J.; Muyldermans, S.; Wyns, L.; Redfield, C.; Matagne, A.; Robinson, C. V.; Dobson, C. M. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 2003, 424, 783-788.
160. Zhou, C.; Emadi, S.; Sierks, M. R.; Messer, A. A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol. Ther. 2004, 10, 1023-1031.
161. Kayed, R.; Sokolov, Y.; Edmonds, B.; Mclntire, T. M.; Milton, S. C.; Hall, J. E.; Glabe, C. G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem. 2004, 279, 46363-46366.
162. Tewari, D.; Notkins, A. L.; Zhou, P. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene. J. Gene Med. 2003, 5, 182-189.
163. Marasco, W. A.; LaVecchio, J.; Winkler, A. Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS. J. Immunol. Methods 1999, 231, 223-238.
164. Wheeler, Y. Y.; Kute, T. E.; Willingham, M. C.; Chen, S. Y.; Sane, D. C. Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. FASEB J. 2003, 17, 1733-1735.
165. Wheeler, Y. Y.; Chen, S. Y.; Sane, D. C. Intrabody and intrakine strategies for molecular therapy. Mol. Ther. 2003, 8, 355-366.
166. Beyer, W. E.; Palache, A. M.; Luchters, G.; Nauta, J.; Osterhaus, A. D. Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res. 2004, 103, 125-132.
167. Wood, S. J.; Maleeff, B.; Hart, T.; Wetzel, R. Physical, morphological and functional differences between ph 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Abeta. J. Mol. Biol. 1996, 256, 870-877.
168. Zurdo, J.; Guijarro, J. I.; Jimenez, J. L.; Saibil, H. R.; Dobson, C. M. Dependence on solution conditions of aggregation and amyloid formation by an SH3 domain. J. Mol. Biol. 2001, 311, 325-340.
169. Clarke, A. R.; Jackson, G. S.; Collinge, J. The molecular biology of prion propagation. Philos. Trans. R. Soc. London, Ser. B: Biol. Sci. 2001, 356, 185-195.
170. Hill, A. F.; Collinge, J. Strain variations and species barriers. Contrib. Microbiol. 2001, 7, 48-57.
171. Collinge, J. Prion diseases of humans and animals: their causes and molecular basis. Annu. Rev. Neurosci. 2001, 24, 519-550.
172. Jackson, G. S.; Collinge, J. The molecular pathology of CJD: old and new variants. Mol. Pathol. 2001, 54, 393-399.
173. Chien, P.; Weissman, J. S.; DePace, A. H. Emerging principles of conformation-based prion inheritance. Annu. Rev. Biochem. 2004, 73, 617-656.
174. Johnson, R. T. Prion diseases. Lancet Neurol. 2005, 4, 635-642.
175. Latouche, M.; Fragner, P.; Martin, E.; El Hachimi, K. H.; Zander, C.; Sittler, A.; Ruberg, M.; Brice, A.; Stevanin, G. Polyglutamine and polyalanine expansions in ataxin7 result in different types of aggregation and levels of toxicity. Mol. Cell. Neurosci. 2006, 31, 438-445.
176. Hartley, D. M.; Walsh, D. M.; Ye, C. P.; Diehl, T.; Vasquez, S.; Vassilev, P. M.; Teplow, D. B.; Selkoe, D. J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 1999, 19, 8876-8884.
177. Bahadi, R.; Farrelly, P. V.; Kenna, B. L.; Kourie, J. I.; Tagliavini, F.; Forloni, G.; Salmona, M. Channels formed with a mutant prion protein PrP(82-146) homologous to a 7-kDa fragment in diseased brain of GSS patients. Am. J. Physiol.: Cell. Physiol. 2003, 285, C862-872.
178. Micelli, S.; Meleleo, D.; Picciarelli, V.; Gallucci, E. Effect of sterols on beta-amyloid peptide (AbetaP 1-40) channel formation and their properties in planar lipid membranes. Biophys. J. 2004, 86, 2231-2237.
179. Rochet, J. C.; Outeiro, T. F.; Conway, K. A.; Ding, T. T.; Volles, M. J.; Lashuel, H. A.; Bieganski, R. M.; Lindquist, S. L.; Lansbury, P. T. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci. 2004, 23, 23-34.
180. Lin, H.; Bhatia, R.; Lal, R. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J. 2001, 15, 2433-2444.
181. Green, J. D.; Kreplak, L.; Goldsbury, C.; Li Blatter, X.; Stolz, M.; Cooper, G. S.; Seelig, A.; Kistler, J.; Aebi, U. Atomic force microscopy reveals defects within mica supported lipid bilayers induced by the amyloidogenic human amylin peptide. J. Mol. Biol. 2004, 342, 877-887.
182. Selkoe, D. J. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med. 2004, 140, 627-638.
183. Bhatia, R.; Lin, H.; Lal, R. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. FASEB J. 2000, 14, 1233-1243.
184. Ding, T. T.; Lee, S. J.; Rochet, J. C.; Lansbury, P. T., Jr. Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry 2002, 41, 10209-10217.
185. Torchilin, V. P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006, 8, 343-375.
186. Noguchi, H.; Matsumoto, S. Protein transduction technology: a novel therapeutic perspective. Acta Med. Okayama 2006, 60, 1-11.
187. Varga, C. M.; Wickham, T. J.; Lauffenburger, D. A. Receptor-mediated targeting of gene delivery vectors: insights from molecular mechanisms for improved vehicle design. Biotechnol. Bioeng. 2000, 70, 593-605.
188. Winterhalter, M.; Lasic, D. D. Liposome stability and formation: experimental parameters and theories on the size distribution. Chem. Phys. Lipids 1993, 64, 35-43.
189. Lasic, D. D. Liposomes: From Physics to Applications; Elsevier Sci. Publ.: Amsterdam, 1993.
190. Torchilin, V. P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discovery 2005, 4, 145-160.
191. Khaw, B. A.; Vural, I.; daSilva, J.; Torchilin, V. P. Use of cytoskeleton-specific immunoliposomes for preservation of cell viability and gene delivery. STP Pharma. Sci. 2000, 10, 279-283.
192. Torchilin, V. P.; Weissig, V. Polymeric micelles for the delivery of poorly soluble drugs. In Controlled Drug Delivery: Designing Technologies for the Future; Park, K., Mrsny, R. J., Eds.; American Chemical Society: Washington, DC, 2000; pp 297-313.
193. Elouahabi, A.; Ruysschaert, J. M. Formation and intracellular trafficking of lipoplexes and polyplexes. Mol. Ther. 2005, 11, 336-347.
194. Kerkis, A.; Hayashi, M. A.; Yamane, T.; Kerkis, I. Properties of cell penetrating peptides (CPPs). IUBMB Life 2006, 58, 7-13.
195. Brinton, R. D. A women's health issue: Alzheimer's disease and strategies for maintaining cognitive health. Int. J. Fertil. Women's Med. 1999, 44, 174-185.
196. Gozes, I. Neuroprotective peptide drug delivery and development: potential new therapeutics. Trends Neurosci. 2001, 24, 700-705.
197. Gozes, I.; Brenneman, D. E.; Geppetti, P.; Kastin, A. J.; Mains, R. E.; Moody, T. W.; Seroogy, K.; Spier, A. D.; Zimmermann, M. Neuropeptides: brain messengers of many faces. Trends Neurosci. 2001, 24, 687-690.
198. Kroll, R. A.; Pagel, M. A.; Muldoon, L. L.; Roman-Goldstein, S.; Fiamengo, S. A.; Neuwelt, E. A. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery 1998, 43, 879-886; discussion 886-879.
199. Downs-Kelly, E.; Jones, M. Z.; Alroy, J.; Cavanagh, K. T.; King, B.; Lucas, R. E.; Baker, J. C.; Kraemer, S. A.; Hopwood, J. J. Caprine mucopolysaccharidosis HID: a preliminary trial of enzyme replacement therapy. J. Mol. Neurosci. 2000, 15, 251-262.
200. Banks, W. A.; Lebel, C. R. Strategies for the delivery of leptin to the CNS. J. Drug Targeting 2002, 10, 297-308.
201. Banks, W. A. Is obesity a disease of the blood-brain barrier? Physiological, pathological, and evolutionary considerations. Curr. Pharm. Des. 2003, 9, 801-809.
202. Kabanov, A. V.; Batrakova, E. V. New technologies for drug delivery across the blood brain barrier. Curr. Pharm. Des. 2004, 10, 1355-1363.
203. Batrakova, E. V.; Vinogradov, S. V.; Robinson, S. M.; Niehoff, M. L.; Banks, W. A.; Kabanov, A. V. Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjugate Chem. 2005, 16, 793-802.
204. Kabanov, A. V.; Alakhov, V. Y. Plutonic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19, 1-72.
205. Kabanov, A. V.; Batrakova, E. V.; Melik-Nubarov, N. S.; Fedoseev, N. A.; Dorodnich, T. Y.; Alakhov, V. Y.; Chekhonin, V. P.; Nazarova, I. R.; Kabanov, V. A. A new class of drug carriers: micelles of poly-(oxyethylene)- poly(oxypropylene) block copolymers as microcontainers for drug targeting from blood in brain. J. Controlled Release 1992, 22, 141-158.
206. Omori, N.; Maruyama, K.; Jin, G.; Li, F.; Wang, S. J., Hamakawa, Y.; Sato, K.; Nagano, I.; Shoji, M.; Abe, K. Targeting of post-ischemic cerebral endothelium in rat by liposomes bearing polyethylene glycol-coupled transferrin. Neurol. Res. 2003, 25, 275-279.
207. Shi, N.; Zhang, Y.; Zhu, C.; Boado, R. J.; Pardridge, W. M. Brain-specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U.S.A. 2001, 90, 12754-12759.
208. Huwyler, J.; Wu, D.; Pardridge, W. M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 14164-14169.
209. Huwyler, J.; Cerletti, A.; Fricker, G.; Eberle, A. N.; Drewe, J. By-passing of P-glycoprotein using immunoliposomes. J. Drug Targeting 2002, 10, 73-79.
210. Wu, D.; Song, B. W.; Vinters, H. V.; Pardridge, W. M. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J Drug Targeting 2002, 10, 239-245.
211. Wu, D.; Boado, R. J.; Pardridge, W. M. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J. Pharmacol. Exp. Ther. 1996, 276, 206-211.
212. Gosk, S.; Vermehren, C.; Storm, G.; Moos, T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab. 2004, 24, 1193-1204.
213. Vinogradov, S. V.; Batrakova, E. V.; Kabanov, A. V. Nanogels for oligonucleotide delivery to the brain. Bioconjugate Chem. 2004, 15, 50-60.
214. Nguyen, H. K.; Lemieux, P.; Vinogradov, S. V.; Gebhart, C. L.; Guerin, N.; Paradis, G.; Bronich, T. K.; Alakhov, V. Y.; Kabanov, A. V. Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther. 2000, 7, 126-138.
215. Jaturanpinyo, M.; Harada, A.; Yuan, X.; Kataoka, K. Preparation of bionanoreactor based on core-shell structured polyion complex micelles entrapping trypsin in the core cross-linked with glutaraldehyde. Bioconjugate Chem. 2004, 15, 344-348.
216. Harada, A.; Kataoka, K. Novel polyion complex micelles entrapping enzyme molecules in the core. 2. Characterization of the micelles prepared at nonstoichiometric mixing ratios. Langmuir 1999, 15, 4208-4212.
217. Roy, S.; Zhang, K.; Roth, T.; Vinogradov, S.; Kao, R. S.; Kabanov, A. Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides. Nat. Biotechnol. 1999, 17, 476-479.
218. Harada-Shiba, M.; Yamauchi, K.; Harada, A.; Takamisawa, I.; Shimokado, K.; Kataoka, K. Polyion complex micelles as vectors in gene therapy- pharmacokinetics and in vivo gene transfer. Gene Ther. 2002, 9, 407-414.
219. Junghans, M.; Loitsch, S. M.; Steiniger, S. C.; Kreuter, J.; Zimmer, A. Cationic lipid-protamine-DNA (LPD) complexes for delivery of antisense c-myc oligonucleotides. Eur. J. Pharm. Biopharm. 2005, 60, 287-294.
220. Cohen-Krausz, S.; Saibil, H. R. Three-dimensional structural analysis of amyloid fibrils by electron microscopy. In Protein Misfolding, Aggregation and Conformational Diseases. Part A: Protein Aggregation and Conformational Diseases; Uversky, V. N., Fink, A. L., Eds.; Springer, New York, 2006; In press.